Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and <i>FGFR1</i> rearrangement-Reference-Cited by-同舟云学术

Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement

Published:2023-06-24 Issue:9 Volume:64 Page:1605-1610
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Yan Yiru¹²,Qu Shiqiang¹²³,Liu Jinqin¹²,Li Chengwen⁴,Yan Xiao⁵,Xu Zefeng¹²³,Qin Tiejun³,Jia Yujiao⁴,Pan Lijuan³,Gao Qingyan³^ORCID,Jiao Meng³,Li Bing¹²³,Gale Robert Peter⁶,Xiao Zhijian¹²³⁴

Affiliation:

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China

2. Tianjin Institutes of Health Science, Tianjin, P.R. China

3. MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China

4. Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China

5. Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo Clinical Research Center for Hematologic Malignancies, Ningbo, P.R. China

6. Centre for Hematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, United Kingdom

Funder

CAMS Initiative Fund for Medical Sciences

Haihe Laboratory of Cell Ecosystem Innovation Fund

Clinical research fund from National Clinical Research Center for Blood Diseases

National Natural Science Funds

National Institute of Health Research (NIHR) Biomedical Research Center

Ministry of Science and Technology of China

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology